Literature DB >> 28945679

Resurgence of Pertussis and Emergence of the Ptxp3 Toxin Promoter Allele in South Italy.

Daniela Loconsole1, Anna Lisa De Robertis1, Anna Morea1, Angela Metallo1, Pier Luigi Lopalco2, Maria Chironna1.   

Abstract

BACKGROUND: Despite universal immunization programs, pertussis remains a major public health concern. This study aimed to describe the pertussis epidemiology in the Puglia region in 2006-2015 and to identify recent polymorphisms in Bordetella pertussis virulence-associated genes.
METHODS: The pertussis cases in 2006-2015 were identified from the National Hospital Discharge Database and the Information System of Infectious Diseases. Samples of pertussis cases in 2014-2016 that were confirmed by the Regional Reference Laboratory were subjected to ptxA, ptxP and prn gene sequencing and, in 10 cases, multiple-locus variable-number tandem repeat analysis.
RESULTS: In Puglia in 2006-2015, the pertussis incidence rose from an average of 1.39/100,000 inhabitants in 2006-2013 to 2.56-2.54/100,000 in 2014-2015. In infants <1 year of age, the incidence rose from an average of 60.4/100,000 infants in 2006-2013 to 149.9/100,000 in 2015. Of the 661 cases recorded in 2006-2015, 80.3% required hospitalization; of these, 45.4% were <1 year of age. Of the 80 sequenced samples, the allelic profile ptxA1-ptxP3-prn2 was detected in 74. This variant was detected in both vaccinated and unvaccinated people. Six Bordetella pertussis samples were prn deficient. The multiple-locus variable-number tandem repeat analysis cases exhibited multiple-locus variable-number tandem repeat analysis-type 27.
CONCLUSIONS: The pertussis incidence in Puglia has risen. The hypervirulent strain was also found in vaccinated people. This suggests bacterial adaptation to the vaccine and raises questions about acellular vaccine effectiveness. Prevention of infant pertussis cases is best achieved by immunizing the pregnant mother. Enhanced surveillance and systematic laboratory confirmation of pertussis should be improved in Italy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28945679     DOI: 10.1097/INF.0000000000001804

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

Review 1.  Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Authors:  Kevin Markey; Catpagavalli Asokanathan; Ian Feavers
Journal:  Toxins (Basel)       Date:  2019-07-17       Impact factor: 4.546

2.  Trends in Hospital Admissions for Pertussis Infection: A Nationwide Retrospective Observational Study in Italy, 2002-2016.

Authors:  Fabiana Fiasca; Giovanni Gabutti; Antonella Mattei
Journal:  Int J Environ Res Public Health       Date:  2019-11-15       Impact factor: 3.390

3.  Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines.

Authors:  Aldert Zomer; Nao Otsuka; Yukihiro Hiramatsu; Kazunari Kamachi; Naoko Nishimura; Takao Ozaki; Jan Poolman; Jeroen Geurtsen
Journal:  Microb Genom       Date:  2018-05-17

4.  High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016.

Authors:  Lijun Li; Jikui Deng; Xiang Ma; Kai Zhou; Qinghong Meng; Lin Yuan; Wei Shi; Qing Wang; Yue Li; Kaihu Yao
Journal:  Emerg Infect Dis       Date:  2019-12       Impact factor: 6.883

5.  Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection.

Authors:  Elisabetta Pandolfi; Nadia Panera; Anna Alisi; Emanuela Carloni; Luisa Russo; Ilaria Campagna; Caterina Rizzo; Carlo Concato; Giulia Linardos; Livia Piccioni; Sally Jackson; Alberto Villani; Fabio Midulla; Alberto E Tozzi
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

6.  Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.

Authors:  Francisco Carriquiriborde; Pablo Martin Aispuro; Nicolás Ambrosis; Eugenia Zurita; Daniela Bottero; María Emilia Gaillard; Celina Castuma; Erika Rudi; Aníbal Lodeiro; Daniela F Hozbor
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.